Beverly Schaefer
Pediatric Hematology-Oncology · Buffalo, NYNPI 1699091272
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. CSL Behring accounts for 72.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $68,072 and has fallen 76.4% since, to $16,047 in 2025. Among pediatric hematology-oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $717.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$86K
- Octapharma USA, Inc.$17K
- Sanofi$7K
- HEMA Biologics, LLC$6K
- Genentech USA, Inc.$2K
- Bayer$1K
- plus $478 from 11 others
Across 3 payments — averaging $975.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$3K
What the payments were for
- Consulting fees$30,60126%
- Speaking & faculty fees$71,70060%
- Travel & lodging$13,82812%
- Food & beverage$3,1573%
- Education$4610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 91 | $86,283 |
| Octapharma USA, Inc. | 44 | $17,019 |
| Sanofi | 8 | $7,164 |
| HEMA Biologics, LLC | 3 | $6,031 |
| Genentech USA, Inc. | 2 | $1,747 |
| Bayer | 1 | $1,024 |
| Jazz Pharmaceuticals Inc. | 2 | $131 |
| Novo Nordisk | 4 | $101 |
| Genentech, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Shire North American Group Inc | 1 | $25 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Kedrion Biopharma, Inc. | 1 | $23 |
| Biomarin Pharmaceutical Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMGENIX$81,577
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$9,172
- Idelvion$6,147
- SevenFact$6,000
- NUWIQ$3,716
- FIBRYGA & BALFAXAR$3,606
- HEMLIBRA$1,735
- Jivi$1,024
- DEFITELIO$106
How this compares
$119,746 in reported general payments places this provider in the 95th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Other pediatric hematology-oncology in Buffalo
- Kara KellyBuffalo$70K
- Matthew BarthBuffalo$43K
- Nataliya BuxbaumBuffalo$5K
- Mitchell CairoHawthorne$1.1M
- Sujit ShethNew York$359K
- Jaap Jan BoelensNew York$303K
- Mary SugrueGarden City$253K
- James BusselNew York$204K
- Saara KavianyNew York$144K
- Gary BrittenhamNew York$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.